Abstract
The aim of the present study was to evaluate the clinical activity and side effects of a combination chemotherapy consisting of a five-day continuous infusion of fluorouracil and i.v. vinorelbine in metastatic previously treated breast cancer patients. The patient population was represented by 28 women with evaluable disease, previously subjected to chemotherapy, including anthracycline-containing regimens in 89% of patients. Treatment consisted of five-day infusion of 700 mg/m2/day of fluorouracil and vinorelbine, 20 mg/m2 iv bolus on day 1 and 6. In the absence of Grade > 3 leukopenia and stomatitis, cycles were repeated every three weeks, for a total of six cycles. Four complete and thirteen partial responses were documented, accounting for a response rate of 61% (95% CI: 40.5-78.5); the clinical efficacy was high even in patients unresponsive to prior anthracycline treatment. The median response duration calculated from the first drug injection was 8 months (range 4-11). Treatment was well tolerated, with 4% Grade 4 stomatitis and 20% Grade 3 leukopenia as the main toxic reactions. This drug combination is active in metastatic previously treated breast cancer patients, is devoid of severe side effects, and warrants further testing.
| Original language | English |
|---|---|
| Pages (from-to) | 255-260 |
| Number of pages | 6 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 44 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1997 |
Fingerprint
Keywords
- Chemotherapy
- Fluorouracil (infusion)
- Metastatic breast cancer
- Salvage treatment
- Vinorelbine
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. / Zambetti, M.; Demicheli, R.; De Candis, D.; Antonelli, G.; Giacobone, A.; Terenziani, M.; Laffranchi, A.; Garbagnati, F.; Biasi, S.; Bonadonna, G.
In: Breast Cancer Research and Treatment, Vol. 44, No. 3, 1997, p. 255-260.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients
AU - Zambetti, M.
AU - Demicheli, R.
AU - De Candis, D.
AU - Antonelli, G.
AU - Giacobone, A.
AU - Terenziani, M.
AU - Laffranchi, A.
AU - Garbagnati, F.
AU - Biasi, S.
AU - Bonadonna, G.
PY - 1997
Y1 - 1997
N2 - The aim of the present study was to evaluate the clinical activity and side effects of a combination chemotherapy consisting of a five-day continuous infusion of fluorouracil and i.v. vinorelbine in metastatic previously treated breast cancer patients. The patient population was represented by 28 women with evaluable disease, previously subjected to chemotherapy, including anthracycline-containing regimens in 89% of patients. Treatment consisted of five-day infusion of 700 mg/m2/day of fluorouracil and vinorelbine, 20 mg/m2 iv bolus on day 1 and 6. In the absence of Grade > 3 leukopenia and stomatitis, cycles were repeated every three weeks, for a total of six cycles. Four complete and thirteen partial responses were documented, accounting for a response rate of 61% (95% CI: 40.5-78.5); the clinical efficacy was high even in patients unresponsive to prior anthracycline treatment. The median response duration calculated from the first drug injection was 8 months (range 4-11). Treatment was well tolerated, with 4% Grade 4 stomatitis and 20% Grade 3 leukopenia as the main toxic reactions. This drug combination is active in metastatic previously treated breast cancer patients, is devoid of severe side effects, and warrants further testing.
AB - The aim of the present study was to evaluate the clinical activity and side effects of a combination chemotherapy consisting of a five-day continuous infusion of fluorouracil and i.v. vinorelbine in metastatic previously treated breast cancer patients. The patient population was represented by 28 women with evaluable disease, previously subjected to chemotherapy, including anthracycline-containing regimens in 89% of patients. Treatment consisted of five-day infusion of 700 mg/m2/day of fluorouracil and vinorelbine, 20 mg/m2 iv bolus on day 1 and 6. In the absence of Grade > 3 leukopenia and stomatitis, cycles were repeated every three weeks, for a total of six cycles. Four complete and thirteen partial responses were documented, accounting for a response rate of 61% (95% CI: 40.5-78.5); the clinical efficacy was high even in patients unresponsive to prior anthracycline treatment. The median response duration calculated from the first drug injection was 8 months (range 4-11). Treatment was well tolerated, with 4% Grade 4 stomatitis and 20% Grade 3 leukopenia as the main toxic reactions. This drug combination is active in metastatic previously treated breast cancer patients, is devoid of severe side effects, and warrants further testing.
KW - Chemotherapy
KW - Fluorouracil (infusion)
KW - Metastatic breast cancer
KW - Salvage treatment
KW - Vinorelbine
UR - http://www.scopus.com/inward/record.url?scp=8544247167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8544247167&partnerID=8YFLogxK
U2 - 10.1023/A:1005769604001
DO - 10.1023/A:1005769604001
M3 - Article
C2 - 9266105
AN - SCOPUS:8544247167
VL - 44
SP - 255
EP - 260
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 3
ER -